Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
Myosteatosis is prognostic in metastatic melanoma treated with nivolumab.

Clinical nutrition ESPEN

Youn S, Reif R, Chu MP, Smylie M, Walker J, Eurich DT, Ghosh S, Sawyer MB.
PMID: 33745604
Clin Nutr ESPEN. 2021 Apr;42:348-353. doi: 10.1016/j.clnesp.2021.01.009. Epub 2021 Jan 20.

BACKGROUND: While immunotherapy agents have improved outcomes in metastatic melanoma (MM), predictive biomarkers in these patients are lacking. Parameters identified from body composition analysis, such as low SMD (also termed myosteatosis), may prognosticate MM patients on immunotherapy.METHODS: In this...

Cite
Youn S, Reif R, Chu MP, et al. Myosteatosis is prognostic in metastatic melanoma treated with nivolumab. Clin Nutr ESPEN. 2021;42:348-353doi: 10.1016/j.clnesp.2021.01.009.
Youn, S., Reif, R., Chu, M. P., Smylie, M., Walker, J., Eurich, D. T., Ghosh, S., & Sawyer, M. B. (2021). Myosteatosis is prognostic in metastatic melanoma treated with nivolumab. Clinical nutrition ESPEN, 42348-353. https://doi.org/10.1016/j.clnesp.2021.01.009
Youn, Susie, et al. "Myosteatosis is prognostic in metastatic melanoma treated with nivolumab." Clinical nutrition ESPEN vol. 42 (2021): 348-353. doi: https://doi.org/10.1016/j.clnesp.2021.01.009
Youn S, Reif R, Chu MP, Smylie M, Walker J, Eurich DT, Ghosh S, Sawyer MB. Myosteatosis is prognostic in metastatic melanoma treated with nivolumab. Clin Nutr ESPEN. 2021 Apr;42:348-353. doi: 10.1016/j.clnesp.2021.01.009. Epub 2021 Jan 20. PMID: 33745604.
Copy Download .nbib Format: NLM
Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Cavalieri S, Ronchi S, Barcellini A, Bonora M, Vischioni B, Vitolo V, Villa R, Del Vecchio M, Licitra L, Orlandi E.
PMID: 34506831
Radiother Oncol. 2021 Nov;164:1-5. doi: 10.1016/j.radonc.2021.08.021. Epub 2021 Sep 08.

We analyzed CTCAE adverse events of sequential Carbon Ion radiotherapy (CIRT) and immune checkpoint inhibitors (ICIs) in advanced melanoma patients. The frequencies of early and late adverse events (AEs) were 100% and 82% of patients, respectively. The frequency of...

Cite
Cavalieri S, Ronchi S, Barcellini A, et al. Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. Radiother Oncol. 2021;164:1-5doi: 10.1016/j.radonc.2021.08.021.
Cavalieri, S., Ronchi, S., Barcellini, A., Bonora, M., Vischioni, B., Vitolo, V., Villa, R., Del Vecchio, M., Licitra, L., & Orlandi, E. (2021). Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1641-5. https://doi.org/10.1016/j.radonc.2021.08.021
Cavalieri, Stefano, et al. "Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 164 (2021): 1-5. doi: https://doi.org/10.1016/j.radonc.2021.08.021
Cavalieri S, Ronchi S, Barcellini A, Bonora M, Vischioni B, Vitolo V, Villa R, Del Vecchio M, Licitra L, Orlandi E. Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. Radiother Oncol. 2021 Nov;164:1-5. doi: 10.1016/j.radonc.2021.08.021. Epub 2021 Sep 08. PMID: 34506831.
Copy Download .nbib Format: NLM
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter.

Clinical cancer research : an official journal of the American Association for Cancer Research

Sonbol MB, Halfdanarson TR.
PMID: 32414760
Clin Cancer Res. 2020 May 15;26(10):2433. doi: 10.1158/1078-0432.CCR-20-0443.

No abstract available.

Cite
Sonbol MB, Halfdanarson TR. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clin Cancer Res. 2020;26(10):2433doi: 10.1158/1078-0432.CCR-20-0443.
Sonbol, M. B., & Halfdanarson, T. R. (2020). Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(10), 2433. https://doi.org/10.1158/1078-0432.CCR-20-0443
Sonbol, Mohamad B, and Halfdanarson, Thorvardur R. "Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,10 (2020): 2433. doi: https://doi.org/10.1158/1078-0432.CCR-20-0443
Sonbol MB, Halfdanarson TR. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clin Cancer Res. 2020 May 15;26(10):2433. doi: 10.1158/1078-0432.CCR-20-0443. PMID: 32414760.
Copy Download .nbib Format: NLM
Advances in drug development. BRAF validation in melanoma.

Clinical advances in hematology & oncology : H&O

Flaherty K.
PMID: 20351680
Clin Adv Hematol Oncol. 2010 Jan;8(1):31-4.

No abstract available.

Cite
Flaherty K. Advances in drug development. BRAF validation in melanoma. Clin Adv Hematol Oncol. 2010;8(1):31-4
Flaherty, K. (2010). Advances in drug development. BRAF validation in melanoma. Clinical advances in hematology & oncology : H&O, 8(1), 31-4.
Flaherty, Keith. "Advances in drug development. BRAF validation in melanoma." Clinical advances in hematology & oncology : H&O vol. 8,1 (2010): 31-4.
Flaherty K. Advances in drug development. BRAF validation in melanoma. Clin Adv Hematol Oncol. 2010 Jan;8(1):31-4. PMID: 20351680.
Copy Download .nbib Format: NLM
Rare victory in fight against melanoma.

Nature

Ledford H.
PMID: 20829766
Nature. 2010 Sep 09;467(7312):140-1. doi: 10.1038/467140b.

No abstract available.

Cite
Ledford H. Rare victory in fight against melanoma. Nature. 2010;467(7312):140-1doi: 10.1038/467140b.
Ledford, H. (2010). Rare victory in fight against melanoma. Nature, 467(7312), 140-1. https://doi.org/10.1038/467140b
Ledford, Heidi. "Rare victory in fight against melanoma." Nature vol. 467,7312 (2010): 140-1. doi: https://doi.org/10.1038/467140b
Ledford H. Rare victory in fight against melanoma. Nature. 2010 Sep 09;467(7312):140-1. doi: 10.1038/467140b. PMID: 20829766.
Copy Download .nbib Format: NLM
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Patel SP, Othus M, Chae YK, Kurzrock R.
PMID: 32414761
Clin Cancer Res. 2020 May 15;26(10):2434. doi: 10.1158/1078-0432.CCR-20-0790.

No abstract available.

Cite
Patel SP, Othus M, Chae YK, et al. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020;26(10):2434doi: 10.1158/1078-0432.CCR-20-0790.
Patel, S. P., Othus, M., Chae, Y. K., Kurzrock, R. (2020). Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(10), 2434. https://doi.org/10.1158/1078-0432.CCR-20-0790
Patel, Sandip P, et al. "Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,10 (2020): 2434. doi: https://doi.org/10.1158/1078-0432.CCR-20-0790
Patel SP, Othus M, Chae YK, Kurzrock R. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020 May 15;26(10):2434. doi: 10.1158/1078-0432.CCR-20-0790. PMID: 32414761.
Copy Download .nbib Format: NLM
Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Nice L, Bycroft R, Wu X, Rai SN, Figg L, Bhandari S, Burd M.
PMID: 33100180
J Oncol Pharm Pract. 2021 Oct;27(7):1736-1742. doi: 10.1177/1078155220968909. Epub 2020 Oct 25.

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have become the standard of care in many cancer types. As the number of patients receiving ICIs for various cancers continues to expand, patients and practitioners should be aware of potentially severe immune-related adverse...

Cite
Nice L, Bycroft R, Wu X, et al. Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors. J Oncol Pharm Pract. 2020;27(7):1736-1742doi: 10.1177/1078155220968909.
Nice, L., Bycroft, R., Wu, X., Rai, S. N., Figg, L., Bhandari, S., & Burd, M. (2021). Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 27(7), 1736-1742. https://doi.org/10.1177/1078155220968909
Nice, Laura, et al. "Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners vol. 27,7 (2021): 1736-1742. doi: https://doi.org/10.1177/1078155220968909
Nice L, Bycroft R, Wu X, Rai SN, Figg L, Bhandari S, Burd M. Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors. J Oncol Pharm Pract. 2021 Oct;27(7):1736-1742. doi: 10.1177/1078155220968909. Epub 2020 Oct 25. PMID: 33100180.
Copy Download .nbib Format: NLM
Paving the way to the cure of melanoma.

Melanoma research

Mouawad R, Spano JP, Khayat D.
PMID: 21045619
Melanoma Res. 2010 Dec;20(6):441-2. doi: 10.1097/CMR.0b013e3283414402.

No abstract available.

Cite
Mouawad R, Spano JP, Khayat D. Paving the way to the cure of melanoma. Melanoma Res. 2010;20(6):441-2doi: 10.1097/CMR.0b013e3283414402.
Mouawad, R., Spano, J. P., & Khayat, D. (2010). Paving the way to the cure of melanoma. Melanoma research, 20(6), 441-2. https://doi.org/10.1097/CMR.0b013e3283414402
Mouawad, Roger, et al. "Paving the way to the cure of melanoma." Melanoma research vol. 20,6 (2010): 441-2. doi: https://doi.org/10.1097/CMR.0b013e3283414402
Mouawad R, Spano JP, Khayat D. Paving the way to the cure of melanoma. Melanoma Res. 2010 Dec;20(6):441-2. doi: 10.1097/CMR.0b013e3283414402. PMID: 21045619.
Copy Download .nbib Format: NLM
Melanogenic inhibitory effects of Triangularin in B16F0 melanoma cells, in vitro and molecular docking studies.

Bioorganic & medicinal chemistry

Santi MD, Peralta MA, Puiatti M, Cabrera JL, Ortega MG.
PMID: 31272835
Bioorg Med Chem. 2019 Aug 15;27(16):3722-3728. doi: 10.1016/j.bmc.2019.06.041. Epub 2019 Jun 27.

The lack of secure therapies for hyperpigmentation disorders, without serious adverse effects, and the latest reports relating melanogenic disorders with development of neurodegenerative diseases, encourage the continuing search for new drugs for the treatment of such disorders. In this...

Cite
Santi MD, Peralta MA, Puiatti M, et al. Melanogenic inhibitory effects of Triangularin in B16F0 melanoma cells, in vitro and molecular docking studies. Bioorg Med Chem. 2019;27(16):3722-3728doi: 10.1016/j.bmc.2019.06.041.
Santi, M. D., Peralta, M. A., Puiatti, M., Cabrera, J. L., & Ortega, M. G. (2019). Melanogenic inhibitory effects of Triangularin in B16F0 melanoma cells, in vitro and molecular docking studies. Bioorganic & medicinal chemistry, 27(16), 3722-3728. https://doi.org/10.1016/j.bmc.2019.06.041
Santi, María D, et al. "Melanogenic inhibitory effects of Triangularin in B16F0 melanoma cells, in vitro and molecular docking studies." Bioorganic & medicinal chemistry vol. 27,16 (2019): 3722-3728. doi: https://doi.org/10.1016/j.bmc.2019.06.041
Santi MD, Peralta MA, Puiatti M, Cabrera JL, Ortega MG. Melanogenic inhibitory effects of Triangularin in B16F0 melanoma cells, in vitro and molecular docking studies. Bioorg Med Chem. 2019 Aug 15;27(16):3722-3728. doi: 10.1016/j.bmc.2019.06.041. Epub 2019 Jun 27. PMID: 31272835.
Copy Download .nbib Format: NLM
Extracting data from a chemotherapy prescription platform for real-world oncology research in the UK: a pilot study.

Future oncology (London, England)

McDonald L, Stein D, Carroll R, Soni M, Schultze A, Ramagopalan S, Wagstaff J.
PMID: 31161801
Future Oncol. 2019 Jul;15(21):2471-2477. doi: 10.2217/fon-2019-0150. Epub 2019 Jun 04.

No abstract available.

Cite
McDonald L, Stein D, Carroll R, et al. Extracting data from a chemotherapy prescription platform for real-world oncology research in the UK: a pilot study. Future Oncol. 2019;15(21):2471-2477doi: 10.2217/fon-2019-0150.
McDonald, L., Stein, D., Carroll, R., Soni, M., Schultze, A., Ramagopalan, S., & Wagstaff, J. (2019). Extracting data from a chemotherapy prescription platform for real-world oncology research in the UK: a pilot study. Future oncology (London, England), 15(21), 2471-2477. https://doi.org/10.2217/fon-2019-0150
McDonald, Laura, et al. "Extracting data from a chemotherapy prescription platform for real-world oncology research in the UK: a pilot study." Future oncology (London, England) vol. 15,21 (2019): 2471-2477. doi: https://doi.org/10.2217/fon-2019-0150
McDonald L, Stein D, Carroll R, Soni M, Schultze A, Ramagopalan S, Wagstaff J. Extracting data from a chemotherapy prescription platform for real-world oncology research in the UK: a pilot study. Future Oncol. 2019 Jul;15(21):2471-2477. doi: 10.2217/fon-2019-0150. Epub 2019 Jun 04. PMID: 31161801.
Copy Download .nbib Format: NLM
Targeting the Microbiome to Overcome Resistance.

Cancer cell

Simpson RC, Shanahan E, Scolyer RA, Long GV.
PMID: 33561397
Cancer Cell. 2021 Feb 08;39(2):151-153. doi: 10.1016/j.ccell.2021.01.016.

Immune checkpoint inhibition has revolutionized the treatment of many cancers, including melanoma. However, primary and acquired resistance remain key challenges for the field. Promising results from a phase I clinical trial recently published in Science highlight the potential of...

Cite
Simpson RC, Shanahan E, Scolyer RA, et al. Targeting the Microbiome to Overcome Resistance. Cancer Cell. 2021;39(2):151-153doi: 10.1016/j.ccell.2021.01.016.
Simpson, R. C., Shanahan, E., Scolyer, R. A., & Long, G. V. (2021). Targeting the Microbiome to Overcome Resistance. Cancer cell, 39(2), 151-153. https://doi.org/10.1016/j.ccell.2021.01.016
Simpson, Rebecca C, et al. "Targeting the Microbiome to Overcome Resistance." Cancer cell vol. 39,2 (2021): 151-153. doi: https://doi.org/10.1016/j.ccell.2021.01.016
Simpson RC, Shanahan E, Scolyer RA, Long GV. Targeting the Microbiome to Overcome Resistance. Cancer Cell. 2021 Feb 08;39(2):151-153. doi: 10.1016/j.ccell.2021.01.016. PMID: 33561397.
Copy Download .nbib Format: NLM
Purple papules during anti-PD1 immunotherapy for metastatic melanoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

De Luca EV, Catapano S, Del Regno L, Di Stefani A, Peris K.
PMID: 33655676
J Dtsch Dermatol Ges. 2021 Apr;19(4):630-632. doi: 10.1111/ddg.14324. Epub 2021 Mar 02.

No abstract available.

Cite
De Luca EV, Catapano S, Del Regno L, et al. Purple papules during anti-PD1 immunotherapy for metastatic melanoma. J Dtsch Dermatol Ges. 2021;19(4):630-632doi: 10.1111/ddg.14324.
De Luca, E. V., Catapano, S., Del Regno, L., Di Stefani, A., & Peris, K. (2021). Purple papules during anti-PD1 immunotherapy for metastatic melanoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 19(4), 630-632. https://doi.org/10.1111/ddg.14324
De Luca, Erika V, et al. "Purple papules during anti-PD1 immunotherapy for metastatic melanoma." Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG vol. 19,4 (2021): 630-632. doi: https://doi.org/10.1111/ddg.14324
De Luca EV, Catapano S, Del Regno L, Di Stefani A, Peris K. Purple papules during anti-PD1 immunotherapy for metastatic melanoma. J Dtsch Dermatol Ges. 2021 Apr;19(4):630-632. doi: 10.1111/ddg.14324. Epub 2021 Mar 02. PMID: 33655676.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries